Daniel Levangie resigned as Non-Executive Director at Renalytix plc.
“Daniel Levangie, tendered his resignation from the Company's Board of Directors and all committees effective on October 31, 2024.”
Renalytix plc — fact timeline
Source-grounded facts extracted from Renalytix plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.
“announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.”
O. James Sterling resigned as Chief Financial Officer at Renalytix plc.
“announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.”
Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.
“On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.”
O. James Sterling resigned as Chief Financial Officer at Renalytix plc.
“On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).”
Renalytix plc entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $15 million (effective 2024-05-15).
“On May 15, 2024, Renalytix plc (the “ Company ”) entered into an at the market offering agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (the “ Agent ”), pursuant to which the Company may issue and sell from time to time, at its option, the Company’s American Depositary Shares (the “ ADSs ”), each representing two ordinary shares (nominal value £0.0025 per share) of the Company, through or to the Agent, as sales agent and/or principal.”
Renalytix plc reported the fiscal third quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss was $7.7 million.
“During the three months ended March 31, 2024, the Company recognized $0.5 million of revenue, compared to $0.7 million for the three months ended March 31, 2023.”
Renalytix plc entered into Placing Agreement with Stifel Nicolaus Europe Limited valued at up to an aggregate of 46,801,872 ordinary shares (effective 2024-03-12).
“on March 12, 2024, Renalytix plc (the “ Company ”) entered into a Placing Agreement (the “ Placing Agreement ”) with Stifel Nicolaus Europe Limited”
Renalytix plc shareholders approved Authorization of disapplication of pre-emption rights limited to shares of maximum aggregate nominal amount of £128,391 at the 2024-04-22 meeting.
“Proposal 4 – Subject to and conditional upon the passing of Proposal 2, to authorize the disapplication of pre-emption rights limited to shares of a maximum aggregate nominal amount of £128,391. For Against Vote Withheld 45,853,622 4,859,914 120,004”
Renalytix plc shareholders approved Authorization of disapplication of statutory pre-emption rights for Second Tranche Placing Shares and shareholder approval pursuant to Nasdaq 20% Rule at the 2024-04-22 meeting.
“Proposal 3 – Subject to and conditional upon the passing of Proposal 1, to authorize (i) the disapplication of statutory pre-emption rights for the issue and allotment of the Second Tranche Placing Shares and (ii) shareholder approval pursuant to the Nasdaq 20% Rule. For Against Vote Withheld 50,072,092 641,404 120,044”
Renalytix plc shareholders approved Authorization of allotment of shares and grant of rights to subscribe for or convert into shares up to aggregate nominal amount of £128,391 and further allotment in connection with pre-emptive offer at the 2024-04-22 meeting.
“Proposal 2 – To authorize the allotment of shares and the grant of rights to subscribe for, or convert any security into, shares of the Company up to an aggregate nominal amount of £128,391 and the allotment of further equity securities up to an aggregate nominal amount of £122,277 in connection with a pre-emptive offer in favor of shareholders. For Against Vote Withheld 45,880,130 4,832,979 120,431”
Renalytix plc shareholders approved Authorization of allotment of ordinary shares up to aggregate nominal amount of £67,039.6025 (Second Tranche Placing Shares) at the 2024-04-22 meeting.
“Proposal 1 – To authorize the al lotment of ordinary shares of £0.0025 each in the capital of the Company up to an aggregate nominal amount of £67,039.6025 (26,815,841 ordinary shares) (the “Second Tranche Placing Shares”). For Against Vote Withheld 50,091,780 621,329 120,431”
Renalytix plc entered into Purchase Agreement with DB Capital Partners Healthcare, L.P. (effective 2024-04-05).
“on April 5, 2024, Renalytix plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with DB Capital Partners Healthcare, L.P. (the “ Purchaser ”)”
Howard Doran was appointed as President at Renalytix plc.
“On April 23, 2024, the Company’s Board of Directors (the “ Board ”) appointed Howard Doran, currently the Company’s Chief Business Officer, to serve as the Company’s President, effective as of April 30, 2024.”
Thomas McLain resigned as President at Renalytix plc.
“On April 17, 2024, Thomas McLain notified the Company that he will resign as President of the Company, effective April 30, 2024”
Renalytix plc amended Bond Agreement Amendment with CVI Investments, Inc. (effective 2024-03-28).
“On March 28, 2024, Renalytix plc (the “ Company ”) entered into a second amendment and restatement agreement (“ Bond Agreement Amendment ”) with CVI Investments, Inc. (" CVI "), which amended the terms of the Company’s existing bond agreement”
Renalytix plc entered into Placing Agreement with Stifel Nicolaus Europe Limited valued at up to an aggregate of 46,801,872 ordinary shares (effective 2024-03-12).
“On March 12, 2024, Renalytix plc (the “ Company ”) entered into a Placing Agreement (the “ Placing Agreement ”) with Stifel Nicolaus Europe Limited (the “ Bookrunner ” or “ Stifel ”), pursuant to which the Company agreed to allot and issue new ordinary shares, nominal value £0.0025 per ordinary share (the “ Placing Shares ”) to certain investors (the “ Placees ”) in an unregistered offering (the “ Private Placement ”), up to an aggregate of 46,801,872 ordinary shares.”
Renalytix plc reported second quarter ended December 31, 2023 results: revenue $0.7 million, net income Net loss was $8.5 million.
“During the three months ended December 31, 2023, we recognized $0.7 million of revenue related to sales of KidneyIntelX.”
Renalytix plc received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“December 22, 2023, Renalytix plc (the “Company”) received two written notices (the “Notices”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that (i) because the closing bid price for the Company’s American Depositary Shares (“ADSs”), each representing two ordinary shares, nominal value £0.0025 per share, was below $1.00 per ADS for at least 30 consecutive business days, the Company did not meet the $1.00 per ADS minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1) the (“Minimum Bid Price Requirement”) and (ii) it is not in”
Renalytix plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“December 22, 2023, Renalytix plc (the “Company”) received two written notices (the “Notices”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that (i) because the closing bid price for the Company’s American Depositary Shares (“ADSs”), each representing two ordinary shares, nominal value £0.0025 per share, was below $1.00 per ADS for at least 30 consecutive business days, the Company did not meet the $1.00 per ADS minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1) the (“Minimum Bid Price Requirement”) and (ii) it is not in”
Renalytix plc shareholders approved To adopt the draft articles of association produced to the AGM as the articles of association of the Company. at the 2023-12-15 meeting.
“Proposal 11 – To adopt the draft articles of association produced to the AGM as the articles of association of the Company. For Against Vote Withheld/Abstain 40,059,859 104,681 46,323”
Renalytix plc shareholders approved To generally and unconditionally authorise the Company to make one or more market purchases on the London Stock Exchange of ordinary shares of £0.0025 each in the capital of the Company on such terms and in such manner as the Directors may from time to time decide. at the 2023-12-15 meeting.
“Proposal 10 – To generally and unconditionally authorise the Company to make one or more market purchases on the London Stock Exchange of ordinary shares of £0.0025 each in the capital of the Company on such terms and in such manner as the Directors may from time to time decide. For Against Vote Withheld/Abstain 39,597,340 51,284 562,239”
Renalytix plc shareholders approved Subject to and conditional upon the passing of Proposal 8 above, to authorise the Directors of the Company to allot equity securities for cash pursuant to the authority conferred by Proposal 8 above and/or sell treasury shares in connection with a pre-emptive offer and otherwise up to a maximum aggr at the 2023-12-15 meeting.
“Proposal 9 – Subject to and conditional upon the passing of Proposal 8 above, to authorise the Directors of the Company to allot equity securities for cash pursuant to the authority conferred by Proposal 8 above and/or sell treasury shares in connection with a pre-emptive offer and otherwise up to a maximum aggregate nominal amount of £85,251.39 . For Against Vote Withheld/Abstain 38,467,804 1,710,946 32,113”
Renalytix plc shareholders approved To authorise the Directors of the Company to (i) allot shares or grant rights to subscribe for, or convert any security into, shares up to a maximum aggregate nominal amount of £85,251.39 and (ii) allot further equity securities up to an aggregate nominal amount of £81,191.80 in connection with a pr at the 2023-12-15 meeting.
“Proposal 8 – To authorise the Directors of the Company to (i) allot shares or grant rights to subscribe for, or convert any security into, shares up to a maximum aggregate nominal amount of £85,251.39 and (ii) allot further equity securities up to an aggregate nominal amount of £81,191.80 in connection with a pre-emptive offer in favour of shareholders. For Against Vote Withheld/Abstain 38,484,392 1,697,234 29,237”
Renalytix plc shareholders approved To authorise the Directors of the Company to determine the auditors’ remuneration for the fiscal year ending June 30, 2024. at the 2023-12-15 meeting.
“Proposal 7 – To authorise the Directors of the Company to determine the auditors’ remuneration for the fiscal year ending June 30, 2024. For Against Vote Withheld/Abstain 40,105,519 77,729 27,615”
Renalytix plc shareholders approved To re-appoint Messrs PKF Littlejohn LLP as auditors to act as such until the conclusion of the next annual general meeting of the Company. at the 2023-12-15 meeting.
“Proposal 6 – To re-appoint Messrs PKF Littlejohn LLP as auditors to act as such until the conclusion of the next annual general meeting of the Company. For Against Vote Withheld/Abstain 40,142,582 37,614 30,667”
Renalytix plc shareholders approved To ratify the selection of Ernst & Young LLP ("EY") as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024. at the 2023-12-15 meeting.
“Proposal 5 – To ratify the selection of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024. For Against Vote Withheld/Abstain 39,266,710 910,387 33,766”
Renalytix plc shareholders approved To re-appoint Catherine Coste as a Director of the Company. at the 2023-12-15 meeting.
“Proposal 3 – To re-appoint Catherine Coste as a Director of the Company. For Against Vote Withheld/Abstain 39,058,428 1,086,363 66,072”
Renalytix plc shareholders approved To approve the Directors’ Remuneration Report set out on pages 38 to 54 (inclusive) of the 2023 U.K. Annual Report. at the 2023-12-15 meeting.
“Proposal 2 – To approve the Directors’ Remuneration Report set out on pages 38 to 54 (inclusive) of the 2023 U.K. Annual Report. For Against Vote Withheld/Abstain 39,959,034 226,856 24,973”
Renalytix plc shareholders approved To receive and adopt the accounts for the year ended June 30, 2023 together with the reports of the Directors and the auditors thereon (the "2023 U.K. Annual Report"). at the 2023-12-15 meeting.
“Proposal 1 – To receive and adopt the accounts for the year ended June 30, 2023 together with the reports of the Directors and the auditors thereon (the “2023 U.K. Annual Report”). For Against Vote Withheld/Abstain 40,118,702 24,743 67,418”
Chirag Parikh resigned as director at Renalytix plc.
“On December 5, 2023, Dr. Chirag Parikh submitted notice of his resignation from the board of directors (the “ Board ”) of Renalytix plc (the “ Company ”), which resignation was effective immediately.”
Renalytix plc reported first quarter ended September 30, 2023 results: revenue $0.5 million, net income Net loss was $10.2 million.
“During the three months ended September 30, 2023, the Company recognized $0.5 million of revenue, compared to $1.0 million for the three months ended September 30, 2022.”
Timothy J. Scannell resigned as Director at Renalytix plc.
“On October 18, 2023, Mr. Timothy J. Scannell submitted notice of his resignation from the board of directors (the “ Board ”) of Renalytix plc (the “ Company ”), which resignation was effective immediately.”
Renalytix plc reported financial results for the fiscal year ended June 30, 2023.
“Renalytix plc (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023”
Howard Doran Jr. was appointed as Chief Business Officer at Renalytix plc.
“On September 1, 2023, the Company’s Board of Directors appointed Howard Doran Jr. as the Company’s Chief Business Officer.”
Catherine Coste was appointed as Director at Renalytix plc.
“On June 30, 2023, Catherine Coste was appointed to the Board of Directors (the “Board”) of Renalytix plc (the “Company”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.